NasdaqCM:EXASBiotechs
Assessing Exact Sciences (EXAS) Valuation After Oncotype DX Reaches 2 Million Patients
What the Oncotype DX milestone means for Exact Sciences (EXAS) investors
Exact Sciences (EXAS) is back in focus after announcing that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than 2 million breast cancer patients worldwide.
For you as an investor, this milestone highlights growing clinical use, long-running evidence behind the assay, and its role in treatment decision support. All of these factors feed directly into perceptions of the company’s...